title: Necrotizing enterocolitis: pathophysiology, platelet-activating factor, and probiotics.
abstract: Although smaller and younger preterm neonates can now survive long term due to advances in neonatal medicine, necrotizing enterocolitis (NEC) continues to plague the clinicians caring for these tiny patients. Research studies have contributed to our understanding of this complex disease, including the role of platelet-activating factor (PAF), but preventative and treatment strategies remain limited. One promising preventative measure in recent years has been enteral supplementation of probiotics, but concerns remain regarding the optimal use of these organisms, and safe administration must be assured. This chapter reviews NEC pathophysiology, including the role of PAF, as well as literature on the use of probiotics in the preterm infant.
authors.affiliation: Department of Pediatrics, NorthShore University HealthSystem, Pritzker School of Medicine, University of Chicago, 2650 Ridge Ave, Walgreen Building, Suite 1505, Evanston, Illinois, USA. bfrost@northshore.org
authors.forename: Brandy L
authors.initials: BL
authors.lastname: Frost
authors.forename: Michael S
authors.initials: MS
authors.lastname: Caplan
mesh_terms: D015415:Biomarkers / Q000378:metabolism; D020345:Enterocolitis, Necrotizing / Q000378:metabolism / Q000503:physiopathology* / Q000517:prevention & control*; D006801:Humans; D007231:Infant, Newborn; D007234:Infant, Premature; D007235:Infant, Premature, Diseases / Q000378:metabolism / Q000503:physiopathology* / Q000517:prevention & control*; D010972:Platelet Activating Factor / Q000378:metabolism*; D019936:Probiotics / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D016896:Treatment Outcome
chemical_list: D015415:Biomarkers; D010972:Platelet Activating Factor